Antifungal therapy: novel drug delivery strategies driven by new targets.

[1]  G. Bills,et al.  Advances in the treatment of invasive fungal disease , 2023, PLoS pathogens.

[2]  C. Neoh,et al.  The antifungal pipeline for invasive fungal diseases: what does the future hold? , 2023, Expert review of anti-infective therapy.

[3]  Tae-Eun Park,et al.  Integrated technologies for continuous monitoring of organs-on-chips: Current challenges and potential solutions. , 2023, Biosensors & bioelectronics.

[4]  J. Orozco,et al.  Antifungal Encapsulated into Ligand-Functionalized Nanoparticles with High Specificity for Macrophages , 2022, Pharmaceutics.

[5]  Yina Cao,et al.  Streptococcus Mutans Membrane Vesicles Enhance Candida albicans Pathogenicity and Carbohydrate Metabolism , 2022, Frontiers in Cellular and Infection Microbiology.

[6]  Changju Chun,et al.  Neutrophil membrane-coated therapeutic liposomes for targeted treatment in acute lung injury , 2022, International journal of pharmaceutics.

[7]  G. Shruthi,et al.  Review of Known and Unknown Facts of Klebsiella Pneumoniae and its Relationship with Antibiotics , 2022, Biomedical and Pharmacology Journal.

[8]  Xuedong Zhou,et al.  Effect of pH-sensitive nanoparticles on inhibiting oral biofilms , 2022, Drug delivery.

[9]  Jinjin Shi,et al.  Augmenting the Precise Targeting of Antimicrobial Peptides (AMPs) and AMP‐Based Drug Delivery via Affinity‐Filtering Strategy , 2022, Advanced Functional Materials.

[10]  Zhiqiang Lin,et al.  Advances in pH-responsive drug delivery systems , 2021, OpenNano.

[11]  Xin Sun,et al.  Characteristics of Invasive Pulmonary Fungal Diseases Diagnosed by Pathological Examination , 2021, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[12]  M. Hoenigl,et al.  The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin , 2021, Drugs.

[13]  C. F. Rodrigues,et al.  Biofilm formation in clinically relevant filamentous fungi: a therapeutic challenge , 2021, Critical reviews in microbiology.

[14]  Kisuk Yang,et al.  Fungal brain infection modelled in a human-neurovascular-unit-on-a-chip with a functional blood–brain barrier , 2021, Nature Biomedical Engineering.

[15]  Conglian Yang,et al.  Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design , 2021, Acta Pharmaceutica Sinica B.

[16]  Tong Yan,et al.  Bioresponsive micro-to-nano albumin-based systems for targeted drug delivery against complex fungal infections , 2021, Acta pharmaceutica Sinica. B.

[17]  M. Nurunnabi,et al.  Delivery strategies of amphotericin B for invasive fungal infections , 2021, Acta pharmaceutica Sinica. B.

[18]  Z. Lewis,et al.  Antifungal Liposomes Directed by Dectin-2 Offer a Promising Therapeutic Option for Pulmonary Aspergillosis , 2021, mBio.

[19]  N. Rosen,et al.  Targeted drug delivery strategies for precision medicines , 2021, Nature Reviews Materials.

[20]  Y. Dufrêne,et al.  Adhesion of Staphylococcus aureus to Candida albicans During Co-Infection Promotes Bacterial Dissemination Through the Host Immune Response , 2021, Frontiers in Cellular and Infection Microbiology.

[21]  G. Rahav,et al.  147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial , 2020 .

[22]  T. Gabaldón,et al.  Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium , 2020, Antibiotics.

[23]  B. S. Unnikrishnan,et al.  Panoramic View of Biological Barricades and Their Influence on Polysaccharide Nanoparticle Transport: An Updated Status in Cancer , 2020 .

[24]  K. Fiedoruk,et al.  Rod-shaped gold nanoparticles exert potent candidacidal activity and decrease the adhesion of fungal cells. , 2020, Nanomedicine.

[25]  J. Geddes-McAlister,et al.  Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance , 2020, mBio.

[26]  J. Copa-Patiño,et al.  In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment of Candida Albicans Biofilms , 2020, Pharmaceutics.

[27]  M. Ghannoum,et al.  Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections , 2020, Antibiotics.

[28]  E. Nice.  The status of proteomics as we enter the 2020s: Towards personalised/precision medicine. , 2020, Analytical biochemistry.

[29]  C. Hall,et al.  The Diverse Roles of Phagocytes During Bacterial and Fungal Infections and Sterile Inflammation: Lessons From Zebrafish , 2020, Frontiers in Immunology.

[30]  E. Uribe-Querol,et al.  Phagocytosis: Our Current Understanding of a Universal Biological Process , 2020, Frontiers in Immunology.

[31]  L. F. Cheow,et al.  The Role of Single-Cell Technology in the Study and Control of Infectious Diseases , 2020, Cells.

[32]  Yijin Ren,et al.  Antifungal‐Inbuilt Metal–Organic‐Frameworks Eradicate Candida albicans Biofilms , 2020, Advanced Functional Materials.

[33]  C. Prestidge,et al.  pH-Responsive copolymer micelles to enhance itraconazole efficacy against Candida albicans biofilms. , 2020, Journal of materials chemistry. B.

[34]  M. Mohammadi,et al.  Nanoparticles and Vaccine Development. , 2020, Pharmaceutical nanotechnology.

[35]  L. Larson,et al.  Hope on the Horizon: Novel Fungal Treatments in Development , 2020, Open forum infectious diseases.

[36]  R. Garcia-Rubio,et al.  The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species , 2020, Frontiers in Microbiology.

[37]  C. Faustino,et al.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy , 2020, Pharmaceutics.

[38]  Lin-Ping Wu,et al.  Grand challenges in nanomedicine. , 2020, Materials science & engineering. C, Materials for biological applications.

[39]  Zhipeng Chen,et al.  Borneol and poly (ethylene glycol) dual modified BSA nanoparticles as an itraconazole vehicle for brain targeting. , 2019, International journal of pharmaceutics.

[40]  Lianhui Wang,et al.  A lipase-responsive antifungal nanoplatform for synergistic photodynamic/photothermal/pharmaco-therapy of azole-resistant Candida albicans infections. , 2019, Chemical communications.

[41]  Z. Lewis,et al.  Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy , 2019, mSphere.

[42]  M. Teixeira,et al.  Characterization of Aspergillus fumigatus Extracellular Vesicles and Their Effects on Macrophages and Neutrophils Functions , 2019, Front. Microbiol..

[43]  Eunjin Choi,et al.  Recent advances in gold nanoparticles for biomedical applications: from hybrid structures to multi-functionality , 2019, Journal of Materials Chemistry B.

[44]  D. Vigetti,et al.  Hyaluronan as tunable drug delivery system. , 2019, Advanced drug delivery reviews.

[45]  I. Jacobsen,et al.  Fungal-Bacterial Interactions in Health and Disease , 2019, Pathogens.

[46]  J. Xie,et al.  Oriented Assembly of Cell-Mimicking Nanoparticles via a Molecular Affinity Strategy for Targeted Drug Delivery. , 2019, ACS nano.

[47]  Marek Grzelczak,et al.  Stimuli-responsive self-assembly of nanoparticles. , 2019, Chemical Society reviews.

[48]  Z. Lewis,et al.  Dectin-1-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy , 2019, mSphere.

[49]  M. Rodrigues,et al.  The Still Underestimated Problem of Fungal Diseases Worldwide , 2019, Front. Microbiol..

[50]  L. Aghebati-Maleki,et al.  Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[51]  Yongzhong Du,et al.  Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy , 2018, Journal of Nanobiotechnology.

[52]  D. Krysan,et al.  Candida–streptococcal interactions in biofilm-associated oral diseases , 2018, PLoS pathogens.

[53]  Yu Shrike Zhang,et al.  Towards the development of human immune-system-on-a-chip platforms , 2018, Drug discovery today.

[54]  J. Xie,et al.  Nanoparticles Targeted against Cryptococcal Pneumonia by Interactions between Chitosan and Its Peptide Ligand. , 2018, Nano letters.

[55]  A. Piccinini,et al.  A complex interplay between the extracellular matrix and the innate immune response to microbial pathogens , 2018, Immunology.

[56]  M. Schaller,et al.  Candida albicans-Induced Epithelial Damage Mediates Translocation through Intestinal Barriers , 2018, mBio.

[57]  Rafik Karaman,et al.  Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review , 2018, Molecules.

[58]  J. Berman,et al.  Localizing Antifungal Drugs to the Correct Organelle Can Markedly Enhance their Efficacy. , 2018, Angewandte Chemie.

[59]  J. Błaszkowska,et al.  Neuroinfections caused by fungi , 2018, Infection.

[60]  Surinder P. Singh,et al.  Silver nanoparticles induced alterations in multiple cellular targets, which are critical for drug susceptibilities and pathogenicity in fungal pathogen (Candida albicans) , 2018, International journal of nanomedicine.

[61]  R. May,et al.  Pathogen-derived extracellular vesicles mediate virulence in the fatal human pathogen Cryptococcus gattii , 2018, Nature Communications.

[62]  P. Singh,et al.  Fabrication of 3-O-sn-Phosphatidyl-L-serine Anchored PLGA Nanoparticle Bearing Amphotericin B for Macrophage Targeting , 2018, Pharmaceutical Research.

[63]  M. C. Furlaneto,et al.  How much do we know about hemolytic capability of pathogenic Candida species? , 2018, Folia Microbiologica.

[64]  N. Zarghami,et al.  Macrophage repolarization using CD44-targeting hyaluronic acid–polylactide nanoparticles containing curcumin , 2017, Artificial cells, nanomedicine, and biotechnology.

[65]  R. Jayakumar,et al.  Carboxymethylated ɩ-carrageenan conjugated amphotericin B loaded gelatin nanoparticles for treating intracellular Candida glabrata infections. , 2017, International journal of biological macromolecules.

[66]  R. Bucki,et al.  Use of magnetic nanoparticles as a drug delivery system to improve chlorhexidine antimicrobial activity , 2017, International journal of nanomedicine.

[67]  Felix Bongomin,et al.  Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision , 2017, Journal of fungi.

[68]  A. Barra,et al.  Organs on chip approach: a tool to evaluate cancer -immune cells interactions , 2017, Scientific Reports.

[69]  Hun Heo,et al.  Targeting and synergistic action of an antifungal peptide in an antibiotic drug‐delivery system , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[70]  A. Mitropoulos,et al.  Price tag in nanomaterials? , 2017, Journal of Nanoparticle Research.

[71]  G. Fricker,et al.  Development and characterization of novel highly‐loaded itraconazole poly(butyl cyanoacrylate) polymeric nanoparticles , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[72]  Lei Wang,et al.  Host Materials Transformable in Tumor Microenvironment for Homing Theranostics , 2017, Advanced materials.

[73]  Sourabh Dhingra,et al.  Regulation of Sterol Biosynthesis in the Human Fungal Pathogen Aspergillus fumigatus: Opportunities for Therapeutic Development , 2017, Front. Microbiol..

[74]  J. Tuszynski,et al.  Software for molecular docking: a review , 2017, Biophysical Reviews.

[75]  Yongzhong Du,et al.  Targeting delivery of simvastatin using ICAM-1 antibody-conjugated nanostructured lipid carriers for acute lung injury therapy , 2017, Drug delivery.

[76]  X. Qu,et al.  Bacterial Hyaluronidase Self-Triggered Prodrug Release for Chemo-Photothermal Synergistic Treatment of Bacterial Infection. , 2016, Small.

[77]  T. Ketela,et al.  Functional Genomic Analysis of Candida albicans Adherence Reveals a Key Role for the Arp2/3 Complex in Cell Wall Remodelling and Biofilm Formation , 2016, PLoS genetics.

[78]  C. Garlanda,et al.  Pentraxins in the activation and regulation of innate immunity , 2016, Immunological reviews.

[79]  P. van Dijck,et al.  Commensal Protection of Staphylococcus aureus against Antimicrobials by Candida albicans Biofilm Matrix , 2016, mBio.

[80]  Yanli Zhao,et al.  Acid-Responsive Polymeric Doxorubicin Prodrug Nanoparticles Encapsulating a Near-Infrared Dye for Combined Photothermal-Chemotherapy , 2016 .

[81]  Dayong Wang,et al.  Synergy Between Polyvinylpyrrolidone-Coated Silver Nanoparticles and Azole Antifungal Against Drug-Resistant Candida albicans. , 2016, Journal of nanoscience and nanotechnology.

[82]  M. Krcmár,et al.  Discovery and Characteristic of Hyaluronidases from Filamentous Fungi , 2016 .

[83]  N. Stone,et al.  Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions , 2016, Drugs.

[84]  G. Geginat,et al.  Prostaglandin E2 from Candida albicans Stimulates the Growth of Staphylococcus aureus in Mixed Biofilms , 2015, PloS one.

[85]  Kerstin Hünniger,et al.  Host response to Candida albicans bloodstream infection and sepsis , 2015, Virulence.

[86]  T. Walsh,et al.  Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus , 2015, Antimicrobial Agents and Chemotherapy.

[87]  M. Ghannoum,et al.  Mycobiota in gastrointestinal diseases , 2015, Nature Reviews Gastroenterology &Hepatology.

[88]  B. Maček,et al.  Global analysis of bacterial membrane proteins and their modifications. , 2015, International journal of medical microbiology : IJMM.

[89]  Feng Chen,et al.  pH and Amphiphilic Structure Direct Supramolecular Behavior in Biofunctional Assemblies , 2014, Journal of the American Chemical Society.

[90]  A. Carrier-Ruiz,et al.  Evidence of involvement of the mannose receptor in the internalization of Streptococcus pneumoniae by Schwann cells , 2014, BMC Microbiology.

[91]  T. Hohl.  Overview of vertebrate animal models of fungal infection. , 2014, Journal of immunological methods.

[92]  Juan Antonio Vizcaíno,et al.  Analysis of the Protein Domain and Domain Architecture Content in Fungi and Its Application in the Search of New Antifungal Targets , 2014, PLoS Comput. Biol..

[93]  A. Tedgui,et al.  Lp-PLA2 et sPLA2 - Biomarqueurs cardiovasculaires , 2014 .

[94]  T. Roemer,et al.  Antifungal drug development: challenges, unmet clinical needs, and new approaches. , 2014, Cold Spring Harbor perspectives in medicine.

[95]  S. Nuding,et al.  Intestinal barrier in inflammatory bowel disease. , 2014, World journal of gastroenterology.

[96]  Darrell J Irvine,et al.  Engineering synthetic vaccines using cues from natural immunity. , 2013, Nature materials.

[97]  C. Lehr,et al.  Pulmonary drug delivery: from generating aerosols to overcoming biological barriers-therapeutic possibilities and technological challenges. , 2013, The Lancet. Respiratory medicine.

[98]  Linyong Zhu,et al.  Highly Discriminating Photorelease of Anticancer Drugs Based on Hypoxia Activatable Phototrigger Conjugated Chitosan Nanoparticles , 2013, Advanced materials.

[99]  B. Peters,et al.  Candida albicans-Staphylococcus aureus Polymicrobial Peritonitis Modulates Host Innate Immunity , 2013, Infection and Immunity.

[100]  David W. Denning,et al.  Hidden Killers: Human Fungal Infections , 2012, Science Translational Medicine.

[101]  Jun Wang,et al.  Bacteria‐Responsive Multifunctional Nanogel for Targeted Antibiotic Delivery , 2012, Advanced materials.

[102]  Xiaoling Fang,et al.  Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. , 2012, Biomaterials.

[103]  B. Klein,et al.  Dendritic cells in antifungal immunity and vaccine design. , 2012, Cell host & microbe.

[104]  M. Kolácková,et al.  Pentraxin 3(PTX 3): An Endogenous Modulator of the Inflammatory Response , 2012, Mediators of inflammation.

[105]  S. Milewski,et al.  Novel dendrimeric lipopeptides with antifungal activity. , 2012, Bioorganic & medicinal chemistry letters.

[106]  M. Harriott,et al.  Importance of Candida-bacterial polymicrobial biofilms in disease. , 2011, Trends in microbiology.

[107]  Y. Abdi,et al.  Light-induced antifungal activity of TiO2 nanoparticles/ZnO nanowires , 2011 .

[108]  Y. Barenholz,et al.  Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa , 2011, PloS one.

[109]  Jeffrey M. Macdonald,et al.  In vivo Hypoxia and a Fungal Alcohol Dehydrogenase Influence the Pathogenesis of Invasive Pulmonary Aspergillosis , 2011, PLoS pathogens.

[110]  Nicolas Anton,et al.  Microencapsulation of nanoemulsions: novel Trojan particles for bioactive lipid molecule delivery , 2011, International journal of nanomedicine.

[111]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[112]  R. A. Cramer,et al.  Implications of hypoxic microenvironments during invasive aspergillosis. , 2011, Medical mycology.

[113]  Bing Gu,et al.  Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles , 2011, Journal of drug targeting.

[114]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[115]  O. Soehnlein,et al.  Contribution of Neutrophils to Acute Lung Injury , 2011, Molecular medicine.

[116]  Duncan W. Wilson,et al.  From Attachment to Damage: Defined Genes of Candida albicans Mediate Adhesion, Invasion and Damage during Interaction with Oral Epithelial Cells , 2011, PloS one.

[117]  S. Filler,et al.  Candida albicans Als3, a Multifunctional Adhesin and Invasin , 2010, Eukaryotic Cell.

[118]  Rongqin Huang,et al.  Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[119]  A. Nobbs,et al.  Interaction of Candida albicans Cell Wall Als3 Protein with Streptococcus gordonii SspB Adhesin Promotes Development of Mixed-Species Communities , 2010, Infection and Immunity.

[120]  C. Leslie,et al.  Pathways Regulating Cytosolic Phospholipase A2 Activation and Eicosanoid Production in Macrophages by Candida albicans , 2010, The Journal of Biological Chemistry.

[121]  D. Andes,et al.  Development and Validation of an In Vivo Candida albicans Biofilm Denture Model , 2010, Infection and Immunity.

[122]  J. Wingard,et al.  Drug-Induced Nephrotoxicity Caused by Amphotericin B Lipid Complex and Liposomal Amphotericin B: A Review and Meta-Analysis , 2010, Medicine.

[123]  George M. Hilliard,et al.  Changes in the Proteome of Candida albicans in Response to Azole, Polyene, and Echinocandin Antifungal Agents , 2010, Antimicrobial Agents and Chemotherapy.

[124]  A. Casadevall,et al.  Extracellular Vesicles from Cryptococcus neoformans Modulate Macrophage Functions , 2010, Infection and Immunity.

[125]  V. Nizet,et al.  Color me bad: microbial pigments as virulence factors. , 2009, Trends in microbiology.

[126]  Hwee Tong Tan,et al.  Membrane proteins and membrane proteomics , 2008, Proteomics.

[127]  M. Nicola,et al.  Bioluminescent Aspergillus fumigatus, a New Tool for Drug Efficiency Testing and In Vivo Monitoring of Invasive Aspergillosis , 2008, Applied and Environmental Microbiology.

[128]  S. Shaikh,et al.  From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico. , 2007, Current pharmaceutical design.

[129]  N. Elguezabal,et al.  Fungicidal Monoclonal Antibody C7 Binds to Candida albicans Als3 , 2007, Infection and Immunity.

[130]  D. Vallenet,et al.  Global comparison of the membrane subproteomes between a multidrug-resistant Acinetobacter baumannii strain and a reference strain. , 2006, Journal of proteome research.

[131]  E. Giralt,et al.  Proteomic analysis of a fraction enriched in cell envelope proteins of Acinetobacter baumannii , 2006, Proteomics.

[132]  L. Nimrichter,et al.  Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage. , 2006, Microbes and infection.

[133]  A. Casadevall,et al.  Induction by Klebsiella aerogenes of a Melanin-Like Pigment in Cryptococcus neoformans , 2006, Applied and Environmental Microbiology.

[134]  T. Andresen,et al.  Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. , 2005, Current drug delivery.

[135]  S. Shoham,et al.  The immune response to fungal infections , 2005, British journal of haematology.

[136]  N. Prasadarao,et al.  N-cadherin Mediates Endocytosis of Candida albicans by Endothelial Cells* , 2005, Journal of Biological Chemistry.

[137]  H. Yatani,et al.  Intercellular Adhesion Molecule 1-Dependent Activation of Interleukin 8 Expression in Candida albicans-Infected Human Gingival Epithelial Cells , 2005, Infection and Immunity.

[138]  R. Sylvester,et al.  Liposomal Nystatin in Patients with Invasive Aspergillosis Refractory to or Intolerant of Amphotericin B , 2004, Antimicrobial Agents and Chemotherapy.

[139]  O. G. Mouritsen,et al.  Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. , 2004, Journal of medicinal chemistry.

[140]  E. Burchielli,et al.  From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 22, 2013. For personal use only. , 2002 .

[141]  A. Wolka,et al.  Pain and the blood-brain barrier: obstacles to drug delivery. , 2003, Advanced drug delivery reviews.

[142]  M. Edgerton,et al.  Candida albicans Ssa1/2p Is the Cell Envelope Binding Protein for Human Salivary Histatin 5* , 2003, Journal of Biological Chemistry.

[143]  Sha Li,et al.  The Study on Brain Targeting of the Amphotericin B Liposomes , 2003, Journal of drug targeting.

[144]  C. Garlanda,et al.  Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response , 2002, Nature.

[145]  W. Bubb,et al.  Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. , 2002, Microbes and infection.

[146]  A. Casadevall,et al.  Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[147]  B. Goins,et al.  Accumulation of PEG-liposomes in the Inflamed Colon of Rats: Potential for Therapeutic and Diagnostic Targeting of Inflammatory Bowel Diseases , 2002, Journal of drug targeting.

[148]  Y. Katare,et al.  Ligand directed macrophage targeting of amphotericin B loaded liposomes. , 2000, International journal of pharmaceutics.

[149]  C. M. Gupta,et al.  Tuftsin-bearing liposomes in treatment of macrophage-based infections. , 2000, Advanced drug delivery reviews.

[150]  W. Bubb,et al.  Heteronuclear NMR studies of metabolites produced by Cryptococcus neoformans in culture media: Identification of possible virulence factors , 1999, Magnetic Resonance in Medicine.

[151]  Y. Pathak,et al.  Current Challenges and Future Directions in Nanomedicine , 2021, Emerging Technologies for Nanoparticle Manufacturing.

[152]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[153]  Yong Hu,et al.  Hyaluronic acid-modified Fe3O4@Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors. , 2015, Biomaterials.

[154]  A. Singh,et al.  Overview of Fungal Lipase: A Review , 2011, Applied Biochemistry and Biotechnology.

[155]  S. Frede,et al.  Regulation of hypoxia-inducible factors during inflammation. , 2007, Methods in enzymology.

[156]  L. Chen,et al.  DNA Fragment Encoding Human IL-1β 163–171 Peptide Enhances the Immune Responses Elicited in Mice by DNA Vaccine against Foot-and-Mouth Disease , 2004, Veterinary Research Communications.